These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 32253095)
1. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095 [TBL] [Abstract][Full Text] [Related]
2. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). Fensome A; Ambler CM; Arnold E; Banker ME; Brown MF; Chrencik J; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gopalsamy A; Hayward MM; Hegen M; Hollingshead BD; Jussif J; Knafels JD; Limburg DC; Lin D; Lin TH; Pierce BS; Saiah E; Sharma R; Symanowicz PT; Telliez JB; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X; Zhang L J Med Chem; 2018 Oct; 61(19):8597-8612. PubMed ID: 30113844 [TBL] [Abstract][Full Text] [Related]
3. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3. Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455 [TBL] [Abstract][Full Text] [Related]
4. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Norman P Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156 [TBL] [Abstract][Full Text] [Related]
5. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. Chough C; Joung M; Lee S; Lee J; Kim JH; Kim BM Bioorg Med Chem; 2018 May; 26(8):1495-1510. PubMed ID: 29452839 [TBL] [Abstract][Full Text] [Related]
7. Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design. Jang WD; Kim JT; Son HY; Park SY; Cho YS; Koo TS; Lee H; Kang NS Bioorg Med Chem Lett; 2015 Sep; 25(18):3947-52. PubMed ID: 26231159 [TBL] [Abstract][Full Text] [Related]
8. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease. Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547 [TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors. Yogo T; Nagamiya H; Seto M; Sasaki S; Shih-Chung H; Ohba Y; Tokunaga N; Lee GN; Rhim CY; Yoon CH; Cho SY; Skene R; Yamamoto S; Satou Y; Kuno M; Miyazaki T; Nakagawa H; Okabe A; Marui S; Aso K; Yoshida M J Med Chem; 2016 Jan; 59(2):733-49. PubMed ID: 26701356 [TBL] [Abstract][Full Text] [Related]
10. A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor. Menet CJ J Med Chem; 2018 Oct; 61(19):8594-8596. PubMed ID: 30252456 [No Abstract] [Full Text] [Related]
11. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model. Liang J; Van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair WS; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Goodacre S; Ghilardi N; MacLeod C; Johnson A; Bir Kohli P; Lai Y; Lin Z; Mantik P; Menghrajani K; Nguyen H; Peng I; Sambrone A; Shia S; Smith J; Sohn S; Tsui V; Ultsch M; Williams K; Wu LC; Yang W; Zhang B; Magnuson S Bioorg Med Chem Lett; 2017 Sep; 27(18):4370-4376. PubMed ID: 28830649 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366 [TBL] [Abstract][Full Text] [Related]
13. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability. Kim H; Kim MK; Choo H; Chong Y Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178 [TBL] [Abstract][Full Text] [Related]
14. Lead identification of novel and selective TYK2 inhibitors. Liang J; Tsui V; Van Abbema A; Bao L; Barrett K; Beresini M; Berezhkovskiy L; Blair WS; Chang C; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liimatta M; Mantik P; Menghrajani K; Murray J; Sambrone A; Xiao Y; Shia S; Shin Y; Smith J; Sohn S; Stanley M; Ultsch M; Zhang B; Wu LC; Magnuson S Eur J Med Chem; 2013 Sep; 67():175-87. PubMed ID: 23867602 [TBL] [Abstract][Full Text] [Related]
15. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069 [TBL] [Abstract][Full Text] [Related]
16. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold. Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909 [TBL] [Abstract][Full Text] [Related]
17. Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors. Lu K; Wu W; Zhang C; Liu Z; Xiao B; Yuan Z; Li A; Chen D; Zhai X; Jiang Y Bioorg Med Chem Lett; 2020 Jul; 30(14):127225. PubMed ID: 32527540 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum. Norman P Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423 [TBL] [Abstract][Full Text] [Related]
20. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]